可資比較公司及佰翱得的各估值詳情概述如下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關收購佰翱得82.54%股份構成關連交易 茲提述本公司日期為2025年10月28日內容有關收購佰翱得82.54%股份的公告 （「該公告」）。除另有界定者外，本公告所用詞彙與該公告所用者具有相同涵義。 除該公告所披露的資料外，本公司謹此提供有關本公司達致本次收購的對價時所 考慮因素的其他詳情。 於釐定本次收購的對價時，本公司已基於其對CRO服務市場的了解及其自身於該 業務的經驗，對佰翱得進行全面估值。誠如該公告所披露，本公司透過與在同行 業經營的四家可資比較公司進行比較而達致其對佰翱得的估值，該等公司均已上 市，就比較而言可提供公開可得且可靠的財務數據。下文概述 ...

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關收購佰翱得82.54%股份構成關連交易 茲提述本公司日期為2025年10月28日內容有關收購佰翱得82.54%股份的公告 （「該公告」）。除另有界定者外，本公告所用詞彙與該公告所用者具有相同涵義。 除該公告所披露的資料外，本公司謹此提供有關本公司達致本次收購的對價時所 考慮因素的其他詳情。 於釐定本次收購的對價時，本公司已基於其對CRO服務市場的了解及其自身於該 業務的經驗，對佰翱得進行全面估值。誠如該公告所披露，本公司透過與在同行 業經營的四家可資比較公司進行比較而達致其對佰翱得的估值，該等公司均已上 市，就比較而言可提供公開可得且可靠的財務數據。下文概述所有經選定可資比 較公司的主要營業地點位於中國，並經營與佰翱得業務相似的CRO業務，且均為 上市公司中業務最接近佰翱得業務的上市公司。由於市銷率及市盈率是評估CRO 業務常用的財務指標，因此我們在對佰翱得的全面估值中參考該等可資比較公司 的市銷率及市盈率 ...

Group 1 - Kanglong Chemical (03759.HK) has seen a decline of over 5% in its stock price, with a cumulative drop exceeding 15% within the month [1] - As of the latest update, the stock is down 5.41%, trading at 22.04 HKD, with a transaction volume of 129 million HKD [1]

Group 1 - The core point of the article is that 康龙化成 (Kanglong Chemical) has seen a significant decline in its stock price, dropping over 5% in a single day and more than 15% in the month due to a share reduction announcement by major shareholders [1] - As of the report, 康龙化成's stock is trading at 22.04 HKD with a trading volume of 129 million HKD [1] - The shareholders, 深圳市信中康成投资合伙企业 and its acting party, plan to reduce their holdings by up to 26.67 million shares, which represents 1.5% of the company's total share capital [1] Group 2 - 华西证券 (Huaxi Securities) has released a report indicating that 康龙化成's third-quarter performance meets expectations, with new orders accelerating [1] - The report suggests that due to the rapid growth in orders and ongoing cost reduction efforts, 康龙化成 is expected to maintain its revenue guidance of 12% to 16% over the next 25 years, indicating a trend of marginal improvement in future performance [1]

Core Viewpoint - 康龙化成's stock has experienced a significant decline, dropping over 5% in a single day and more than 15% in the month, attributed to a share reduction announcement by major shareholders [1] Group 1: Stock Performance - 康龙化成's stock price is currently at 22.04 HKD, reflecting a decrease of 5.41% [1] - The total trading volume for the stock reached 1.29 billion HKD [1] Group 2: Shareholder Actions - Major shareholders, 深圳市信中康成投资合伙企业 and its acting party, plan to reduce their holdings by up to 26.67 million shares, which represents 1.5% of the total share capital [1] Group 3: Company Performance Outlook - 华西证券 reported that 康龙化成's Q3 performance met expectations, with new orders showing an accelerating trend [1] - The company maintains a revenue growth guidance of 12% to 16% over the next 25 years, indicating a potential for marginal improvement in future performance [1]

Group 1 - The core point of the article is that shareholders of Kanglong Chemical intend to reduce their holdings, leading to a decline in both A-shares and H-shares, which fell over 5% and reached new lows since mid-September [1] - The shareholders, Shenzhen Xincheng Kangcheng Investment Partnership and Shenzhen Xincheng Longcheng Investment Partnership, plan to reduce their holdings by up to 26.6729 million shares, accounting for no more than 1.5% of the company's total share capital [1] - The company has announced a total of four share reduction plans in the past three years, indicating a pattern of shareholder divestment [1]

Core Viewpoint - Kanglong Chemical experienced a decline of 5.02% on November 17, with a stock price of 29.90 yuan per share and a total market capitalization of 53.168 billion yuan [1] Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business segments include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and large molecule and cell & gene therapy services (3.28%) [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Kanglong Chemical, with the Xinda Health China Mixed A Fund (003291) holding 959,400 shares, representing 5.41% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.5159 million yuan as of the latest data [2] Fund Manager Performance - The fund manager Li Junzhou has been in position for 165 days, with a total fund size of 634 million yuan and a best return of 11.17% during his tenure [3] - Yang Ke, another fund manager, has been in position for 5 years and 190 days, managing a total fund size of 1.324 billion yuan, with a best return of 43.77% during his tenure [3]

格隆汇11月17日丨根据联交所最新权益披露资料显示，2025年11月12日，康龙化成(03759.HK)获Norges Bank在场内以每股均价23.8072港元增持70.02万股，涉资约1667万港元。 | 芸植序线 | 大股東/董事/最高行政人員名 作出技擺的 買入 / 变出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的海關事件的日 相關法國股 債權證權益 | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 調金関上述*註 有投票權股期(日/月/ 份權益 | | | | | | | 份百分比 年) | | | | | | | ( 96 ) 日 1985 | | CS20251113E00453 Norges Bank | 700.200(L) | 1101(L) | | HKD 23.8072 | 18,270,424(L) 6.21(L)12/11/2025 | 增持后，Norges Bank最新持股数目为18,270,424股，持股比例由5.97%上升至6.21%。 ...

Core Viewpoint - The company 康龙化成 (300759.SZ) has received a share reduction plan notification from its major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder 信中康成 holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce its holdings by up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shareholder 信中龙成 holds 28,498,500 shares, about 1.60% of the total share capital, and intends to reduce its holdings by up to 17,781,955 shares, representing 1% of the total share capital, within the same three-month period [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has announced that its major shareholders, 深圳市信中康成投资合伙企业 and 深圳市信中龙成投资合伙企业, plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - 深圳市信中康成 plans to reduce its holdings by up to 8.891 million shares, which represents 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成 plans to reduce its holdings by up to 17.782 million shares, which represents 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]